NG2 and DLL3 CAR-T cells / SZGIMI - LARVOL DELTA

NG2 and DLL3 CAR-T Cells Targeting Melanoma (clinicaltrials.gov) - P1/2 | N=100 | Terminated | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2029 ➔ Jul 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2028 ➔ Jul 2026

Trial completion date • Trial primary completion date • Trial termination • Tumor mutational burden • Melanoma • Oncology • Solid Tumor • DLL3